531 related articles for article (PubMed ID: 25559924)
1. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and natural course of craniocervical junction anomalies during growth in patients with osteogenesis imperfecta.
Arponen H; Mäkitie O; Haukka J; Ranta H; Ekholm M; Mäyränpää MK; Kaitila I; Waltimo-Sirén J
J Bone Miner Res; 2012 May; 27(5):1142-9. PubMed ID: 22258757
[TBL] [Abstract][Full Text] [Related]
3. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
4. Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
Vuorimies I; Arponen H; Valta H; Tiesalo O; Ekholm M; Ranta H; Evälahti M; Mäkitie O; Waltimo-Sirén J
Bone; 2017 Jan; 94():29-33. PubMed ID: 27725317
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
6. Skull base abnormalities in osteogenesis imperfecta: a cephalometric evaluation of 54 patients and 108 control volunteers.
Kovero O; Pynnönen S; Kuurila-Svahn K; Kaitila I; Waltimo-Sirén J
J Neurosurg; 2006 Sep; 105(3):361-70. PubMed ID: 16961127
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
9. Monitoring Skull Base Abnormalities in Children with Osteogenesis Imperfecta - Review of Current Practice and a Suggested Clinical Pathway.
Wadanamby S; El Garwany S; Connolly D; Arundel P; Bishop NJ; DeVile CJ; Calder AD; Crowe B; Burren CP; Saraff V; ; Offiah AC
Bone; 2022 Jan; 154():116235. PubMed ID: 34688943
[TBL] [Abstract][Full Text] [Related]
10. Craniocervical abnormalities in osteogenesis imperfecta type V.
Ludwig K; Seiltgens C; Ibba A; Saran N; Ouellet JA; Glorieux F; Rauch F
Osteoporos Int; 2022 Jan; 33(1):177-183. PubMed ID: 34350492
[TBL] [Abstract][Full Text] [Related]
11. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
Bone; 2016 May; 86():53-7. PubMed ID: 26927310
[TBL] [Abstract][Full Text] [Related]
12. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Sousa T; Bompadre V; White KK
J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
[TBL] [Abstract][Full Text] [Related]
13. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
14. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.
Trejo P; Fassier F; Glorieux FH; Rauch F
J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684
[TBL] [Abstract][Full Text] [Related]
15. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
16. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Zeitlin L; Rauch F; Plotkin H; Glorieux FH
Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
[TBL] [Abstract][Full Text] [Related]
18. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Yamashita S
Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
[TBL] [Abstract][Full Text] [Related]
19. Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta patients: a retrospective cross-sectional study.
Arponen H; Mäkitie O; Waltimo-Sirén J
BMC Musculoskelet Disord; 2014 Dec; 15():428. PubMed ID: 25494634
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
